VIS954 for Treating Inflammatory Skin Problems

Key Inclusion Criteria

1. Participant must be at least 18 years of age or have reached the legal age of consent in their country, whichever is higher.
2. HS- Adults with moderate-to-severe HS of at least 6 months' duration, classified as Hurley Stage II or III, with an inadequate response, intolerance, or contraindication to prior standard systemic antibiotic therapy.
3. PG-Adults with clinically confirmed moderate-to-severe ulcerative PG requiring systemic therapy and presenting with at least one active ulcerative lesion of less than 6 months' duration.
4. BP-Adults with newly diagnosed or relapsing classical BP, confirmed by clinical presentation and direct immunofluorescence and/or BP180/BP230 serology, with moderate disease activity.

Key Exclusion Criteria

1. Participants cannot join the study if they have another active skin condition, medical condition, or mental health condition that, in the study doctor's opinion, could affect the study results, increase safety risks, require restricted medications during the study, or make participation unsuitable.
2. HS-Lack of adequate response, as determined by the investigator.
3. PG-Presence of active infection involving the target ulcer or non-PG mimics that may interfere with assessment of pyoderma gangrenosum disease activity or treatment response.
4. BP- Participants with any pemphigoid disease other than classic BP, BP secondary to medications, or any severe comorbid illness.